A 'cochlear implant for vision' just won EU approval. The U.S. could follow in 2027.

The first commercial retinal implant designed for age-related macular degeneration cleared a major regulator on Wednesday. The mechanism behind it explains why the indication stays narrow.

Science Corporation's Prima device received CE Mark approval in Europe for atrophic, or "dry," age-related macular degeneration, the leading cause of central vision loss in older adults. The company says the implant partially restores central vision in patients with advanced disease, enough for reading books and discerning road signs. Science Corporation is targeting a 2027 U.S. launch contingent on the FDA pathway, STAT+ reports.

Founder and CEO Max Hodak has framed the device as a "cochlear implant for vision." The analogy is a handle for non-specialists, not a description of how the device works. Prima is a 2-millimeter-wide photovoltaic chip implanted beneath the retina, sitting where the macula used to be. It has no external camera, no battery, no cable. Incoming light through the eye powers the chip and is converted into electrical pulses that stimulate the surviving cells downstream of the dead macula: the part of the retina responsible for sharp central vision that atrophies in advanced dry AMD.

That architecture is the part most wire coverage will skip. Earlier retinal prostheses used an external camera mounted on glasses to capture images and inductive coils to power the implant. Prima skips both the camera and the coil. The eye itself is the image source, and the chip is its own power supply.

A 4-year follow-up study in Ophthalmology Science00046-0/fulltext) reported prosthetic visual acuity in atrophic AMD patients fitted with the PRIMA subretinal microchip. The foundational work on photovoltaic subretinal stimulation came from the Palanker lab at Stanford. Science Corporation's own pages document the CE Mark application and the Series C financing that carried the research from bench to bedside, along with a New England Journal of Medicine milestone the company highlighted.

The narrowness of the indication is the honesty check. Prima is approved for atrophic AMD with central vision loss in patients whose downstream retinal cells are still intact. It doesn't help patients with wet AMD, the rarer form treated with anti-VEGF injections. It doesn't help patients with optic-nerve disease, glaucoma, or retinitis pigmentosa. It doesn't restore peripheral vision. "Partially restores central vision" isn't a synonym for cures blindness, and the company uses that language.

timeline is a target, not a guarantee. Science Corporation's 2027 window depends on which FDA pathway the device lands in, and on what the agency concludes from the existing European and clinical data. The company hasn't announced an FDA filing. The honest framing is that European clearance has happened, and U.S. access is the next thing the company is working toward.

For the AMD population, Prima is the first commercial option that addresses central-vision loss at the source rather than magnifying what remains. The "cochlear for vision" line is shorthand for a 25-year bet on a specific architecture: a chip that uses the eye as both camera and power source, and that lives in exactly the spot the disease destroys. That architecture is also why the device can't be generalized into a broader vision-loss cure. The mechanism and the indication are the same sentence.